Text Size

Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00540059
First received: October 3, 2007
Last updated: October 4, 2007
Last verified: August 2007
History of Changes
  Purpose

Purpose of this study is the evaluation of QoL, tolerability and use of Zoladex 10,8 SafeSystem for advanced PCa under naturalistic conditions


Condition
Prostate Carcinoma

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Quality Assurance Project in Patients With Advanced Prostate Carcinoma - Evaluation of Tolerability, Quality of Life and Usage of Zoladex 10,8 SafeSystem

Resource links provided by NLM:

MedlinePlus related topics: Prostate Cancer
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Enrollment: 1950
Study Start Date: June 2005
  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with PCa, who will be treated with Zoladex 10,8 SafeSystem based on the current SPC
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00540059

Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: H Brasch AstraZeneca
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00540059     History of Changes
Other Study ID Numbers: Zx-002
Study First Received: October 3, 2007
Last Updated: October 4, 2007
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by AstraZeneca:
Prostate carcinoma
LHRH
Zoladex

Additional relevant MeSH terms:
Carcinoma
Prostatic Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
 Genital Diseases, Male
Prostatic Diseases
Goserelin
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 16, 2013